The European Patent Office has published a new patent application, EP4494701A2, detailing novel therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases. The application was filed by Boehringer Ingelheim International GmbH and lists several inventors. The publication date is March 18, 2026, and it is designated for a wide range of European states.

This patent publication represents a new intellectual property filing related to pharmaceutical development. For compliance officers in the pharmaceutical sector, this indicates ongoing innovation and potential future market exclusivity for specific treatments. While this is a patent application and not a regulatory rule, it signifies a development that may impact future drug development and market access strategies. No immediate compliance actions are required, but it is relevant for competitive intelligence and R&D strategy.